TargAnox Raises Series A

TargAnox, a Boston-based drug startup focused on oxidative stress, has raised $5.1 million in Series A funding, according to Xconomy. Ascent Biomedical Ventures led the round, and was joined by Partners Innovation Fund.

Leave a Reply

PE HUB Community

Join the 12523 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget